Leading science, pioneering therapies
CRM Publications

ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli.

TitleErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli.
Publication TypeJournal Article
Year of Publication2006
AuthorsTapinos N, Ohnishi M, Rambukkana A
JournalNat Med
Date Published2006 Aug
KeywordsAnimals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Butadienes, Cells, Cultured, Cercopithecus aethiops, Coculture Techniques, COS Cells, Demyelinating Diseases, Enzyme Activation, Enzyme Inhibitors, HeLa Cells, Humans, Leprosy, Mice, Mice, Knockout, Mice, Nude, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mycobacterium leprae, Nitriles, Pyrimidines, Pyrroles, Rats, Receptor, erbB-2, Schwann Cells, Sciatic Nerve, Signal Transduction

Demyelination is a common pathologic feature in many neurodegenerative diseases including infection with leprosy-causing Mycobacterium leprae. Because of the long incubation time and highly complex disease pathogenesis, the management of nerve damage in leprosy, as in other demyelinating diseases, is extremely difficult. Therefore, an important challenge in therapeutic interventions is to identify the molecular events that occur in the early phase before the progression of the disease. Here we provide evidence that M. leprae-induced demyelination is a result of direct bacterial ligation to and activation of ErbB2 receptor tyrosine kinase (RTK) signaling without ErbB2-ErbB3 heterodimerization, a previously unknown mechanism that bypasses the neuregulin-ErbB3-mediated ErbB2 phosphorylation. MEK-dependent Erk1 and Erk2 (hereafter referred to as Erk1/2) signaling is identified as a downstream target of M. leprae-induced ErbB2 activation that mediates demyelination. Herceptin (trastuzumab), a therapeutic humanized ErbB2-specific antibody, inhibits M. leprae binding to and activation of ErbB2 and Erk1/2 in human primary Schwann cells, and the blockade of ErbB2 activity by the small molecule dual ErbB1-ErbB2 kinase inhibitor PKI-166 (ref. 11) effectively abrogates M. leprae-induced myelin damage in in vitro and in vivo models. These results may have implications for the design of ErbB2 RTK-based therapies for both leprosy nerve damage and other demyelinating neurodegenerative diseases.

Alternate JournalNat. Med.
PubMed ID16892039
Grant ListR01 A145816 / / PHS HHS / United States
R01 NS45187 / NS / NINDS NIH HHS / United States
Publication institute